FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD

The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension– a progressive and life-threatening condition
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news